November 20, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for December 14, 2006 Subscribe to this News Feed  
 

Consumers Need Not Wait for Resveratrol to be Approved as a Drug

Download this press release as an Adobe PDF document.

Research-grade resveratrol capsules are available and consumers need not wait for red wine pills to become a drug to obtain a high-quality dietary supplement. Responding to consumer demand, Longevinex® introduces a premium higher-dosage resveratrol capsule.

San Dimas, CA (PRWeb) December 14, 2006 -- While the demand for red wine resveratrol pills has heightened with the recent publication of a report showing resveratrol overcame the adverse effects of a high-fat diet in animals, many consumers question the quality of red wine resveratrol pills and believe that many brands provide less than the labeled amount of resveratrol and others provide only grape skin powder, not resveratrol. Some doctors and pharmacists are suggesting consumers wait till resveratrol becomes a prescription drug, an approval process that takes seven years or more.

Longevinexflyercollage.jpg

However, consumers do not need to wait for resveratrol to be approved as a doctor-dispensed medicine to obtain reliable dosages of this natural molecule, says Bill Sardi, president of Resveratrol Partners LLC, maker of Longevinex® capsules, the premium red wine resveratrol supplement.

Environmental factors may degrade resveratrol.* Longevinex uses a proprietary process to protect its ingredients from degradation is the only resveratrol dietary supplement that is encapsulated without exposure to light, heat or oxygen and sealed in an airtight, opaque capsule (Licaps®, Capsugel®, trademarks used under license). Resveratrol in Longevinex® capsules has been shown to be stable for more than 2 years, retaining 96% or more of its potency. (Independent lab report)

Another independent laboratory test confirms that Longevinex® activates the Sirtuin 1 DNA-repair "survival" gene as well as research-grade resveratrol. With evidence that the inclusion of an accompanying antioxidant increases activation of the Sirtuin 1 gene,** Longevinex also includes IP6 rice bran, a powerful antioxidant.

Because of a consumer demand for higher-dose supplements, the dosage of resveratrol in Longevinex® has now been increased from 40 to 100 milligrams per capsule.

To match the dosage found to be effective in the animal experiment published in Nature Magazine, 180 milligrams daily dose of trans resveratrol is suggested for a 160-pound adult human. Resveratrol capsules should be consumed with meals, says Bill Sardi, because that is when the French drink their red wine. The French exhibit superior cardiovascular health because of resveratrol in their red wine.

To learn more about Longevinex, go to www.longevinex.com.

References: *Chinese Journal Chromatography (Se Pu) 22:583-8, 2004; J Agriculture Food Chemistry 51:5867-70, 2003; Journal Chromatography A. November 30, 2006; Czech Journal of Food Sciences 22, 166-68, 2004; **Mechanisms Aging Development 127: 618-27, 2006.

Contact: Bill Sardi, 909 596 9507

# # #

Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1Qcm9mLUVtcHQtVGhpci1NYWduLVplcm8=


See the original story at: http://www.prweb.com/releases/2006/12/prweb491762.htm
Other Releases by this Member
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Bill Sardi
Resveratrol Partners LLC
909 596 9507
Email us Here

Longevinex: The only research-grade airtight resveratrol capsule
Longevinex captures and preserves resveratrol like a corked bottle or wine or a sealed research vial.
Uploaded: Dec 14, 2006
File Name: Longevinexflyercollage.jpg

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright